BioSpace News Archive

Proposed pro-health plan legislation imposes federal payment rate setting on physicians, leading to serious consequences to the entire health care system for years to come

Ipsen officially opens North American headquarters at One Main Street and recently renovated R&D and Global External Innovation and Partnering facilities at 650 East Kendall Street

Hill-Rom Holdings, Inc. , which recently rebranded as Hillrom, will host its fiscal third quarter 2019 earnings conference call and webcast on Friday, August 2, 2019, beginning at 7:30 a.m. / 8:30 a.m.

Company will also host a scientific symposium and interactive panel discussion focused on enhanced echocardiography

Adaptive Biotechnologies announced that it has secured contractual agreements or positive medical policies for the clonoSEQ® Assay with several of the largest national private health insurers in the United States, as well as significant regional coverage, bringing the total number of covered lives to more than 140 million.

Velan Capital, L.P., one of the largest stockholders of Progenics Pharmaceuticals, Inc., comprised of successful specialty pharmaceutical operators and financial services experts, announced that it has issued a detailed presentation on the Company in connection with the upcoming 2019 Annual Meeting of Stockholders to be held on July 11, 2019

Canopy Growth Corporation announced its financial results for the fourth quarter and fiscal year ended March 31, 2019.

Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, has announced that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement, as detailed in the company press release.

Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement.

Avacta Group plc (AIM: AVCT), the developer of Affimer®biotherapeutics and research reagents, and Selexis, a pioneering life sciences company and global leader in mammalian cell line generation technology, have partnered to develop the Chinese hamster ovary (CHO) cell line that will be used to manufacture Avacta’s first Affimer clinical candidate for first-time-in-human clinical trials